Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Artele Biosciences, Inc. on June 19, 2020. The company is incorporated in Nevada and its common stock (ARTL) and warrants (ARTLW) trade on The Nasdaq Stock Market, LLC. The filing details the voting results for director elections, equity plan amendments, and auditor ratification.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of four specific matters voted upon by shareholders. Approximately 54.19% of outstanding shares were represented at the meeting.
- Election of Directors: All six nominees (Gregory D. Gorgas, Connie Matsui, Steven Kelly, John W. Beck, R. Martin Emanuele, and Douglas Blayney) were elected. Each received over 1 million votes in favor, with "Votes Against" ranging from approximately 37,000 to 43,000 per nominee.
- Equity Plan Amendment (Share Increase): Shareholders approved an amendment to increase the 2018 Equity Incentive Plan reserve by 425,000 shares. The vote was 1,003,038 For vs. 48,010 Against.
- Equity Plan Amendment (Automatic Increase): Shareholders approved a provision for automatic annual increases to the plan's share reserve starting in fiscal year 2021. The increase will be the least of 15% of outstanding shares, 7,500,000 shares, or a board-determined number. The vote was 1,002,363 For vs. 48,486 Against.
- Auditor Ratification: The appointment of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending August 31, 2020, was ratified. The vote was 1,683,490 For vs. 164,303 Against.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is strictly a disclosure of shareholder voting results.
Investor Verification Checklist
- Verify the total number of shares outstanding (3,427,399) as of the record date (April 27, 2020) against the company's most recent 10-K or 10-Q.
- Confirm the implementation of the 425,000 share increase to the 2018 Equity Incentive Plan in subsequent filings.
- Review the specific terms of the automatic annual increase provision approved for the 2021 fiscal year to understand potential future dilution.
- Check the company's latest financial reports for liquidity status, as this 8-K does not provide cash or debt metrics.